Advanced search
Publication Cover
Emerging Microbes & Infections Volume 11, 2022 - Issue 1
Submit an article Journal homepage
5,734
Views
6
CrossRef citations to date
0
Altmetric
Coronaviruses

B cell receptor signatures associated with strong and poor SARS-CoV-2 vaccine responses

Ke Lina Department of Infectious Disease of Huashan Hospital, National Medical Center for Infectious Diseases and Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Yawen Zhoub State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, People’s Republic of ChinaView further author information
,
Jingwen Aia Department of Infectious Disease of Huashan Hospital, National Medical Center for Infectious Diseases and Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Yan A. Wangc CHESS-COVID-19 Group; Liaoning Emergency Treatment and Innovation Center of Public Health Emergencies, The Sixth People's Hospital of Shenyang, Shenyang, People's Republic of ChinaView further author information
,
Senxin Zhangd Department of Mathematics, Shanghai Normal University, Shanghai, People’s Republic of ChinaView further author information
,
Chao Qiua Department of Infectious Disease of Huashan Hospital, National Medical Center for Infectious Diseases and Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Fudan University, Shanghai, People’s Republic of China;e Key Laboratory of Medical Molecular Virology (MOE/MOH) and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Chaoyang Lianf Shanghai Institute of Immunology, State Key Laboratory of Oncogenes and Related Genes, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Bo Gaof Shanghai Institute of Immunology, State Key Laboratory of Oncogenes and Related Genes, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Tingting Liub State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, People’s Republic of ChinaView further author information
,
Hongyu Wanga Department of Infectious Disease of Huashan Hospital, National Medical Center for Infectious Diseases and Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Haocheng Zhanga Department of Infectious Disease of Huashan Hospital, National Medical Center for Infectious Diseases and Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Yi Zhanga Department of Infectious Disease of Huashan Hospital, National Medical Center for Infectious Diseases and Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Zhangfan Fua Department of Infectious Disease of Huashan Hospital, National Medical Center for Infectious Diseases and Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Dan Lic CHESS-COVID-19 Group; Liaoning Emergency Treatment and Innovation Center of Public Health Emergencies, The Sixth People's Hospital of Shenyang, Shenyang, People's Republic of ChinaView further author information
,
Ning Jiangg State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai, People's Republic of ChinaView further author information
,
Jingxin Guoa Department of Infectious Disease of Huashan Hospital, National Medical Center for Infectious Diseases and Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Jing Wua Department of Infectious Disease of Huashan Hospital, National Medical Center for Infectious Diseases and Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Yan O. Wangh Liaoning Emergency Treatment and Innovation Center of Public Health Emergencies, The Sixth People's Hospital of Shenyang, Shenyang, People's Republic of ChinaView further author information
,
Shusen Songc CHESS-COVID-19 Group; Liaoning Emergency Treatment and Innovation Center of Public Health Emergencies, The Sixth People's Hospital of Shenyang, Shenyang, People's Republic of ChinaView further author information
,
Qiang Lic CHESS-COVID-19 Group; Liaoning Emergency Treatment and Innovation Center of Public Health Emergencies, The Sixth People's Hospital of Shenyang, Shenyang, People's Republic of ChinaView further author information
,
Yanan Yini Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Jia Xiaj Department of Nephrology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Yingjie Xui Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Leng-Siew Yeapf Shanghai Institute of Immunology, State Key Laboratory of Oncogenes and Related Genes, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Xiaoqi Zhengd Department of Mathematics, Shanghai Normal University, Shanghai, People’s Republic of ChinaView further author information
,
Ye Guc CHESS-COVID-19 Group; Liaoning Emergency Treatment and Innovation Center of Public Health Emergencies, The Sixth People's Hospital of Shenyang, Shenyang, People's Republic of ChinaView further author information
,
Hongyan Liuc CHESS-COVID-19 Group; Liaoning Emergency Treatment and Innovation Center of Public Health Emergencies, The Sixth People's Hospital of Shenyang, Shenyang, People's Republic of ChinaCorrespondence[email protected]
View further author information
,
Wenhong Zhanga Department of Infectious Disease of Huashan Hospital, National Medical Center for Infectious Diseases and Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Fudan University, Shanghai, People’s Republic of China;e Key Laboratory of Medical Molecular Virology (MOE/MOH) and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;h Liaoning Emergency Treatment and Innovation Center of Public Health Emergencies, The Sixth People's Hospital of Shenyang, Shenyang, People's Republic of China;k National Clinical Research Centre for Aging & Medicine, Huashan Hospital, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
View further author information
&
Fei-Long Mengb State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 452-464 | Received 13 Oct 2021, Accepted 12 Jan 2022, Published online: 04 Feb 2022

References

  • Team CC-VBCI. COVID-19 Vaccine breakthrough infections reported to CDC – United States, January 1–April 30, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(21):792–793.
  • Pollett SD, Richard SA, Fries AC, et al. The SARS-CoV-2 mRNA vaccine breakthrough infection phenotype includes significant symptoms, live virus shedding, and viral genetic diversity. Clin Infect Dis. 2021 Jun 12:ciab543. DOI:10.1093/cid/ciab543.
  • Kroidl I, Mecklenburg I, Schneiderat P, et al. Vaccine breakthrough infection and onward transmission of SARS-CoV-2 Beta (B.1.351) variant, Bavaria, Germany, February to March 2021. Euro Surveill. 2021 Jul;26(30):2100673. DOI:10.2807/1560-7917.ES.2021.26.30.2100673.
  • Strafella C, Caputo V, Guerrera G, et al. Case report: SARS-CoV-2 infection in a vaccinated individual: evaluation of the immunological profile and virus transmission risk. Front Immunol. 2021;12:708820.
  • Duerr R, Dimartino D, Marier C, et al. Dominance of alpha and iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City. J Clin Invest. 2021 Sep 15;131(18):e152702. DOI:10.1172/JCI152702.
  • Hacisuleyman E, Hale C, Saito Y, et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med. 2021;384(23):2212–2218.
  • Estofolete CF, Banho CA, Campos GRF, et al. Case study of two post vaccination SARS-CoV-2 infections with P1 variants in CoronaVac vaccinees in Brazil. Viruses. 2021;13(7):1237.
  • Brodin P, Davis MM. Human immune system variation. Nat Rev Immunol. 2017;17(1):21–29.
  • Chen Y, Zuiani A, Fischinger S, et al. Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production. Cell. 2020;183(6):1496–1507.e16.
  • Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 – preliminary report. N Engl J Med. 2020;383(20):1920–1931.
  • Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020 Oct;586(7830):594–599.
  • Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803–812.
  • Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51.
  • Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592(7855):616–622. doi:10.1038/s41586-021-03324-6.
  • Alt FW, Zhang Y, Meng FL, et al. Mechanisms of programmed DNA lesions and genomic instability in the immune system. Cell. 2013;152(3):417–429.
  • Nielsen SCA, Boyd SD. Human adaptive immune receptor repertoire analysis-past, present, and future. Immunol Rev. 2018;284(1):9–23.
  • Briney B, Inderbitzin A, Joyce C, et al. Commonality despite exceptional diversity in the baseline human antibody repertoire. Nature. 2019;566(7744):393–397.
  • Soto C, Bombardi RG, Branchizio A, et al. High frequency of shared clonotypes in human B cell receptor repertoires. Nature. 2019;566(7744):398–402.
  • Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021 Oct 14;385(16):1474–1484. DOI:10.1056/NEJMoa2109072.
  • Tsang JS, Dobano C, VanDamme P, et al. Improving vaccine-induced immunity: can baseline predict outcome? Trends Immunol. 2020;41(6):457–465.
  • Pulendran B. Immunology taught by vaccines. Science. 2019;366(6469):1074–1075.
  • Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 2019 Mar 13;32(2):e00084–18. DOI:10.1128/CMR.00084-18.
  • Nie J, Li Q, Wu J, et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc. 2020;15(11):3699–3715.
  • Kaplinsky J, Arnaout R. Robust estimates of overall immune-repertoire diversity from high-throughput measurements on samples. Nat Commun. 2016;7:11881.
  • Raybould MIJ, Kovaltsuk A, Marks C, et al. CoV-AbDab: the coronavirus antibody database. Bioinformatics. 2021;37(5):734–735.
  • Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584(7821):437–442.
  • Gao M, Piernas C, Astbury NM, et al. Associations between body-mass index and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 2021;9(6):350–359.
  • Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588(7837):315–320.
  • Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–192.
  • Wong WS, Lo AW, Siu LP, et al. Reference ranges for lymphocyte subsets among healthy Hong Kong Chinese adults by single-platform flow cytometry. Clin Vaccine Immunol. 2013;20(4):602–606.
  • Bolotin DA, Poslavsky S, Mitrophanov I, et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods. 2015;12(5):380–381.
  • Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370(6522):1339–1343.
  • Paschold L, Simnica D, Willscher E, et al. SARS-CoV-2-specific antibody rearrangements in prepandemic immune repertoires of risk cohorts and patients with COVID-19. J Clin Invest. 2021 Jan 4;131(1):e142966. DOI:10.1172/JCI142966.
  • Tsang JS, Schwartzberg PL, Kotliarov Y, et al. Global analyses of human immune variation reveal baseline predictors of postvaccination responses. Cell. 2014;157(2):499–513.
  • Davis MM, Brodin P. Rebooting human immunology. Annu Rev Immunol. 2018;36:843–864.
  • Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 Randomized Clinical trials. JAMA. 2020;324(10):951–960.
  • Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35–45.
  • Han B, Song Y, Li C, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 Dec;21(12):1645–1653. DOI:10.1016/S1473-3099(21)00319-4.
  • Cao Y, Yisimayi A, Bai Y, et al. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. Cell Res. 2021;31(7):732–741.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.